Dyslipidemia in chronic kidney disease: Are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?

Cardiovascular Therapeutics

Volumn 28, Issue 6, 2010, Pages 361-368

  Scarpioni, Roberto ^a   Ricardi, Marco ^a   Melfa, Luigi ^a   Cristinelli, Luciano ^a  

^a GUGLIELMO DA SALICETO HOSPITAL   (Italy)

Author keywords

Cardio vascular risk; Chronic kidney disease; Dialysis; Lipids disorder atherosclerosis; Renal dysfunction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANEMIA; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIALYSIS; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FAMILY HISTORY; HEMODIALYSIS; HUMAN; HYPERTENSION; MALNUTRITION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POST HOC ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78449259952     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00182.x     Document Type: Review

References (48)

1. Wen CP, Cheng TY, Tsai MK, et al,. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 28: 2173 - 2182.
2. Bellizzi V,. G Ital Nefrol 2008; 25 (Suppl 42): S3 - S7.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 17: 3143 - 3421.
4. Wanner C, Krane V, März W, et al,. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 21: 238 - 248. (Pubitemid 41058323)
5. Fellström BC, Jardine AG, Schmieder RE, et al,. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395 - 1407.
6. Rovin BH, Tan LC,. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43: 218 - 225.
7. Abrass CK,. Cellular lipid metabolism and the role of lipid in progressive renal disease. Am J Nephrol 2004; 24: 46 - 53.
8. Vazquez-Pèrez S, Aragoncillo P, De Las Heras N, et al,. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterlaemic rabbits. Nephrol Dial Transplant 2001; 16 (Suppl 1): 40 - 44.
9. Ritz E, Wanner C,. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008; 19: 1065 - 1070.
10. Wanner C, Krane V,. Uremia-specific alterations in lipid metabolism. Blood Purif 2002; 20: 451 - 453.
11. Shurraw S, Tonelli M,. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523 - 539. (Pubitemid 44669427)
12. Vaziri ND, Deng G, Liang K,. Hepatic HDL receptor, SRB1 and ApoA-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462 - 1466.
13. Scarpioni R, Paties C, Bergonzi G,. Dramatic atherosclerotic vascular burden in a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Nephrol Dial Transplant 2008; 23: 1074 - 1075.
14. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G,. Cellular consequences of the association of apoB lipoprotein with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17: 1011 - 1017.
15. Kasiske BL,. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S142 - S156.
16. Scarpioni R,. Therapeutic tools for dyslipidemia in peritoneal dialysis patients. J Nephrol 2009; 22: 46 - 58.
17. Nishizawa Y, Shoji T, Kawagishi T, Morii H,. Atherosclerosis in uremia: Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 1997; 62: S90 - S92.
18. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS,. Effects of pravastatin treatment on lipoprotein subclass profile and particle size in the PLAC-I trial. Atherosclerosis 2002; 160: 41 - 48.
19. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J,. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63: 12 - 23.
20. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296 - 1305.
21. Sarnak MJ, Levey AS, Schoolwerth AC, et al,. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Kidney disease as a risk factor for development of cardiovascular disease (A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention). Circulation 2003; 108: 2154 - 2169.
22. Keane WF, Kasiske BL, O'Donnell MP, Kim Y,. The role of altered lipid metabolism in the progression of renal disease: Experimental evidence. Am J Kidney Dis 1991; 17 (Suppl 1): 38 - 42.
23. Vieira JM, Rodrigues LT, Mantovani E, et al,. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol 2005; 101: 82 - 91.
24. Yoshimura A, Nemoto T, Sugenoya Y, et al,. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int Suppl 1999; 71: S84 - S87.
25. Zhu XY, Daghini E, Chade A, Napoli C, Ritman EL, Lerman A, Lerman LO,. Simvastatin prevents coronary microvascular remodelling in renovascular hypertensive pigs. J Am Soc Nephrol 2007; 18: 1209 - 1217.
26. Scarpioni R, Michieletti E, Pavone L, et al,. Atherosclerotic Renovascular Disease: Medical therapy plus renal artery stenting, compared with medical therapy alone, do not offer more chances in preventing cardio-vascular or renal events. Preliminary results of a prospective, multicenter and randomized trial. World Congress of Nephrology, Milan (Italy) 22-24 May 2009: Abstract #952277. Available from:. [Accessed 21 November 2009.
27. Schaeffner ES, Kurth T, Curhan GC, et al,. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084 - 2091.
28. Shepherd J, Cobbe SM, Ford I, et al,. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 16: 1301 - 1307.
29. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E,. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438 - 445. (Pubitemid 44109954)
30. Tonelli M, Keech A, Shepherd J, et al,. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005; 16: 3748 - 3754.
31. Shepherd J, Kastelein JP, Bittner VA, et al., Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008; 83: 870 - 879.
32. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J,. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007; 49: 373 - 382.
33. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC,. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 22: 645 - 651.
34. Colhoun HM, Betteridge DJ, Durrington PN, et al,. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810 - 819.
35. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC(BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet 2003; 361: 2005 - 2016.
36. Sandhu S, Wiebe N, Fried LF, Tonelli M,. Statins for improving renal outcomes: A meta-analysis J Am Soc Nephrol 2006; 17: 2006 - 2016.
37. Douglas K, O'Malley PG, Jackson JL,. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145: 117 - 124.
38. Tonelli M, Isles C, Craven T, et al,. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 12: 171 - 178.
39. Sever PS, Dahlöf B, Poulter NR, et al,. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial'Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 5: 1149 - 1158. (Pubitemid 36398384)
40. Landray M, Baigent C, Leaper C, et al,. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006; 47: 385 - 395.
41. Prichard SS,. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14 (Suppl 4): S315 - S320.
42. K(DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 (Suppl 3): S1 - S153.
43. Tsimihodimos V, Dounousi E, Siamopoulos KC,. Dyslipidemia in chronic kidney disease: An approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958 - 973.
44. Liu Y, Coresh J, Eustace JA, et al,. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451 - 459.
45. LaRosa JC, Grundy SM, Waters DD, et al,. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425 - 1435.
46. Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, Jacobs C,. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane Collaborative Study. Nephron 1982; 31: 103 - 110.
47. Pfeffer MA, Burdmann EA, Chen CY, et al,. A trial of Darbepoetin Alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019 - 2032.
48. Lam NN, Jain AK, Hackam DG, et al,. Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney Int 2009; 76: 1172 - 1179.